Direction Centrale Du Service De Sante Des Armees
- Address
- lock Available on a paid plan
Dermatology and Skin Inflammation Research
At Direction Centrale Du Service De Sante Des Armees in Toulon, the Dermatology program includes clinical trials focused on skin and connective tissue diseases, especially atopic dermatitis and moderate-to-severe atopic hand eczema. These studies are designed to evaluate new treatment options and better understand how to reduce symptoms and improve day-to-day skin health.
- Atopic dermatitis and atopic hand eczema: testing a new therapy to ease inflammation and improve disease control
- Moderate-to-severe skin disease: comparing treatment effectiveness against placebo in people who may need systemic therapy
Overall, this area reflects a strong interest in improving care for chronic inflammatory skin conditions through more effective and better-targeted treatments.
Cardiovascular and Stroke Prevention Studies
The site also contributes to cardiovascular disease research, with trials centered on preventing recurrent ischemic stroke and reducing risk after transient ischemic attack. The main goal is to find safer and more effective ways to protect patients who remain vulnerable after a recent cerebrovascular event.
- Ischemic stroke and high-risk transient ischemic attack: evaluating a medicine aimed at preventing another clot-related event
- Stroke prevention: comparing treatment effectiveness while also monitoring bleeding risk
This research supports better secondary prevention strategies for patients recovering from acute cerebrovascular disease.
Oncology Research in Lung Cancer
Clinical trials at this hospital/clinic include a major focus on neoplasms, particularly non-small cell lung cancer in both resectable and advanced stages. These studies are testing new combinations and treatment approaches to improve survival and slow disease progression.
- Non-small cell lung cancer: studying newer therapy combinations to see whether they improve disease control
- Stage II and IIIA-B lung cancer: evaluating treatment approaches around surgery to strengthen long-term outcomes
- Advanced nonsquamous lung cancer with KRAS p.G12C and PD-L1 negative status: comparing treatment effectiveness in a harder-to-treat population
Across these oncology studies, investigators are working to identify better options for both earlier and advanced forms of lung cancer, with attention to survival and progression outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 9 therapeutic areas and 15 of 92 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 87 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Direction Centrale Du Service De Sante Des Armees
lock Showing 1 of 30 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy | Merck Sharp & Dohme LLC | Phase II | Not Recruiting | Apr 2021 | Oct 2024 |
IMP list
lock Showing 1 of 92 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 6 | Unknown | 2019-07-22 | 2026-02-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.